

NOVADEL PHARMA INC

Form 8-K

October 16, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) October 15, 2009**

**NOVADEL PHARMA INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other jurisdiction

of incorporation or organization)

**001-32177**

(Commission File No.)

**22-2407152**

(I.R.S. Employer

Identification No.)

**25 Minneakoning Road**

**Flemington, New Jersey 08822**

## Edgar Filing: NOVADEL PHARMA INC - Form 8-K

(Address of principal executive offices) (Zip Code)

(908) 782-3431

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Edgar Filing: NOVADEL PHARMA INC - Form 8-K

### **Item 7.01. Regulation FD Disclosure**

On October 15, 2009, beginning at 9:00 a.m., Eastern Standard Time, the 2009 Annual Meeting of Stockholders of NovaDel Pharma Inc., a Delaware corporation (the Company), was held at the offices of Morgan, Lewis & Bockius LLP, located at 502 Carnegie Center, Princeton, New Jersey 08540. In connection with this meeting, the Company has made available for review on its website an updated copy of its Corporate Presentation at [www.novadel.com](http://www.novadel.com). A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information furnished pursuant to this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

### **Item 8.01 Other Events**

On October 16, 2009, the Company issued a press release to announce that it held its 2009 Annual Meeting of Stockholders.

A copy of the press release is filed herewith as Exhibit 99.2.

### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 NovaDel Pharma Inc. Corporate Presentation dated October 15, 2009.

99.2 Press Release of NovaDel Pharma Inc., dated October 16, 2009, titled NovaDel Holds Annual Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Steven B. Ratoff  
Name: Steven B. Ratoff  
Title: Chairman, Interim Chief Financial Officer, Interim President and Chief Executive Officer

Date: October 16, 2009